Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Net Cash Flow data on record, last reported at -$9.8 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 81.49% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$163.4 million, down 177.94%, while the annual FY2025 figure was -$163.4 million, 177.94% down from the prior year.
  • Net Cash Flow reached -$9.8 million in Q4 2025 per CRNX's latest filing, down from $57.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $341.0 million in Q1 2024 and bottomed at -$170.0 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $442750.0, with a median of -$5.7 million recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 3902.19% in 2024, down 5613.71% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $39.2 million in 2021, then tumbled by 95.5% to $1.8 million in 2022, then tumbled by 5091.37% to -$87.9 million in 2023, then skyrocketed by 40.02% to -$52.7 million in 2024, then surged by 81.49% to -$9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$9.8 million in Q4 2025, $57.2 million in Q3 2025, and -$40.8 million in Q2 2025.